Literature DB >> 24179220

Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus.

Jason S McLellan1, Man Chen, M Gordon Joyce, Mallika Sastry, Guillaume B E Stewart-Jones, Yongping Yang, Baoshan Zhang, Lei Chen, Sanjay Srivatsan, Anqi Zheng, Tongqing Zhou, Kevin W Graepel, Azad Kumar, Syed Moin, Jeffrey C Boyington, Gwo-Yu Chuang, Cinque Soto, Ulrich Baxa, Arjen Q Bakker, Hergen Spits, Tim Beaumont, Zizheng Zheng, Ningshao Xia, Sung-Youl Ko, John-Paul Todd, Srinivas Rao, Barney S Graham, Peter D Kwong.   

Abstract

Respiratory syncytial virus (RSV) is the leading cause of hospitalization for children under 5 years of age. We sought to engineer a viral antigen that provides greater protection than currently available vaccines and focused on antigenic site Ø, a metastable site specific to the prefusion state of the RSV fusion (F) glycoprotein, as this site is targeted by extremely potent RSV-neutralizing antibodies. Structure-based design yielded stabilized versions of RSV F that maintained antigenic site Ø when exposed to extremes of pH, osmolality, and temperature. Six RSV F crystal structures provided atomic-level data on how introduced cysteine residues and filled hydrophobic cavities improved stability. Immunization with site Ø-stabilized variants of RSV F in mice and macaques elicited levels of RSV-specific neutralizing activity many times the protective threshold.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24179220      PMCID： PMC4461862          DOI： 10.1126/science.1243283

Source DB:  PubMed          Journal:  Science        ISSN： 0036-8075            Impact factor:   47.728


  31 in total

1.  Collagen stabilization at atomic level: crystal structure of designed (GlyProPro)10foldon.

Authors:  Jörg Stetefeld; Sabine Frank; Margrit Jenny; Therese Schulthess; Richard A Kammerer; Sergei Boudko; Ruth Landwehr; Kenji Okuyama; Jürgen Engel
Journal:  Structure       Date:  2003-03       Impact factor: 5.006

Review 2.  Antibodies, viruses and vaccines.

Authors:  Dennis R Burton
Journal:  Nat Rev Immunol       Date:  2002-09       Impact factor: 53.106

3.  Philosophy of science. The coordinates of truth.

Authors:  Gary J Nabel
Journal:  Science       Date:  2009-10-02       Impact factor: 47.728

4.  Identification of protective and broadly conserved vaccine antigens from the genome of extraintestinal pathogenic Escherichia coli.

Authors:  Danilo Gomes Moriel; Isabella Bertoldi; Angela Spagnuolo; Sara Marchi; Roberto Rosini; Barbara Nesta; Ilaria Pastorello; Vanja A Mariani Corea; Giulia Torricelli; Elena Cartocci; Silvana Savino; Maria Scarselli; Ulrich Dobrindt; Jörg Hacker; Hervé Tettelin; Luke J Tallon; Steven Sullivan; Lothar H Wieler; Christa Ewers; Derek Pickard; Gordon Dougan; Maria Rita Fontana; Rino Rappuoli; Mariagrazia Pizza; Laura Serino
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-03       Impact factor: 11.205

5.  Cross-neutralization of four paramyxoviruses by a human monoclonal antibody.

Authors:  Davide Corti; Siro Bianchi; Fabrizia Vanzetta; Andrea Minola; Laurent Perez; Gloria Agatic; Barbara Guarino; Chiara Silacci; Jessica Marcandalli; Benjamin J Marsland; Antonio Piralla; Elena Percivalle; Federica Sallusto; Fausto Baldanti; Antonio Lanzavecchia
Journal:  Nature       Date:  2013-08-18       Impact factor: 49.962

6.  Characterization of the carboxypeptidase involved in the proteolytic cleavage of the influenza haemagglutinin.

Authors:  W Garten; H D Klenk
Journal:  J Gen Virol       Date:  1983-10       Impact factor: 3.891

7.  Architecture of respiratory syncytial virus revealed by electron cryotomography.

Authors:  Lassi Liljeroos; Magdalena Anna Krzyzaniak; Ari Helenius; Sarah Jane Butcher
Journal:  Proc Natl Acad Sci U S A       Date:  2013-06-17       Impact factor: 11.205

8.  Structural basis of respiratory syncytial virus neutralization by motavizumab.

Authors:  Jason S McLellan; Man Chen; Albert Kim; Yongping Yang; Barney S Graham; Peter D Kwong
Journal:  Nat Struct Mol Biol       Date:  2010-01-24       Impact factor: 15.369

9.  Structural definition of a conserved neutralization epitope on HIV-1 gp120.

Authors:  Tongqing Zhou; Ling Xu; Barna Dey; Ann J Hessell; Donald Van Ryk; Shi-Hua Xiang; Xinzhen Yang; Mei-Yun Zhang; Michael B Zwick; James Arthos; Dennis R Burton; Dimiter S Dimitrov; Joseph Sodroski; Richard Wyatt; Gary J Nabel; Peter D Kwong
Journal:  Nature       Date:  2007-02-15       Impact factor: 49.962

10.  Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120.

Authors:  Leopold Kong; Jeong Hyun Lee; Katie J Doores; Charles D Murin; Jean-Philippe Julien; Ryan McBride; Yan Liu; Andre Marozsan; Albert Cupo; Per-Johan Klasse; Simon Hoffenberg; Michael Caulfield; C Richter King; Yuanzi Hua; Khoa M Le; Reza Khayat; Marc C Deller; Thomas Clayton; Henry Tien; Ten Feizi; Rogier W Sanders; James C Paulson; John P Moore; Robyn L Stanfield; Dennis R Burton; Andrew B Ward; Ian A Wilson
Journal:  Nat Struct Mol Biol       Date:  2013-05-26       Impact factor: 15.369
View more
  367 in total

1.  Influences on the Design and Purification of Soluble, Recombinant Native-Like HIV-1 Envelope Glycoprotein Trimers.

Authors:  Rajesh P Ringe; Anila Yasmeen; Gabriel Ozorowski; Eden P Go; Laura K Pritchard; Miklos Guttman; Thomas A Ketas; Christopher A Cottrell; Ian A Wilson; Rogier W Sanders; Albert Cupo; Max Crispin; Kelly K Lee; Heather Desaire; Andrew B Ward; P J Klasse; John P Moore
Journal:  J Virol       Date:  2015-08-26       Impact factor: 5.103

2.  Characterization of Pre-F-GCN4t, a Modified Human Respiratory Syncytial Virus Fusion Protein Stabilized in a Noncleaved Prefusion Conformation.

Authors:  Normand Blais; Martin Gagné; Yoshitomo Hamuro; Patrick Rheault; Martine Boyer; Ann-Muriel Steff; Guy Baudoux; Vincent Dewar; Josée Demers; Jean-Louis Ruelle; Denis Martin
Journal:  J Virol       Date:  2017-06-09       Impact factor: 5.103

3.  The Heptad Repeat C Domain of the Respiratory Syncytial Virus Fusion Protein Plays a Key Role in Membrane Fusion.

Authors:  Imogen M Bermingham; Keith J Chappell; Daniel Watterson; Paul R Young
Journal:  J Virol       Date:  2018-01-30       Impact factor: 5.103

4.  Model Building and Refinement of a Natively Glycosylated HIV-1 Env Protein by High-Resolution Cryoelectron Microscopy.

Authors:  Jeong Hyun Lee; Natalia de Val; Dmitry Lyumkis; Andrew B Ward
Journal:  Structure       Date:  2015-09-17       Impact factor: 5.006

5.  A vulnerable, membrane-proximal site in human respiratory syncytial virus F revealed by a prefusion-specific single-domain antibody.

Authors:  Iebe Rossey; Ching-Lin Hsieh; Koen Sedeyn; Marlies Ballegeer; Bert Schepens; Jason S Mclellan; Xavier Saelens
Journal:  J Virol       Date:  2021-03-10       Impact factor: 5.103

Review 6.  Structural, antigenic and immunogenic features of respiratory syncytial virus glycoproteins relevant for vaccine development.

Authors:  José A Melero; Vicente Mas; Jason S McLellan
Journal:  Vaccine       Date:  2016-09-28       Impact factor: 3.641

Review 7.  Strategies to guide the antibody affinity maturation process.

Authors:  Nicole A Doria-Rose; M Gordon Joyce
Journal:  Curr Opin Virol       Date:  2015-04-24       Impact factor: 7.090

8.  A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults.

Authors:  Antonios O Aliprantis; Christine A Shaw; Paul Griffin; Nicholas Farinola; Radha A Railkar; Xin Cao; Wen Liu; Jeffrey R Sachs; Christine J Swenson; Heather Lee; Kara S Cox; Daniel S Spellman; Colleen J Winstead; Igor Smolenov; Eseng Lai; Tal Zaks; Amy S Espeseth; Lori Panther
Journal:  Hum Vaccin Immunother       Date:  2020-10-29       Impact factor: 3.452

Review 9.  Lamb model of respiratory syncytial virus-associated lung disease: insights to pathogenesis and novel treatments.

Authors:  Mark R Ackermann
Journal:  ILAR J       Date:  2014

10.  Mutations in the Fusion Protein of Measles Virus That Confer Resistance to the Membrane Fusion Inhibitors Carbobenzoxy-d-Phe-l-Phe-Gly and 4-Nitro-2-Phenylacetyl Amino-Benzamide.

Authors:  Michael N Ha; Sébastien Delpeut; Ryan S Noyce; Gary Sisson; Karen M Black; Liang-Tzung Lin; Darius Bilimoria; Richard K Plemper; Gilbert G Privé; Christopher D Richardson
Journal:  J Virol       Date:  2017-11-14       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.